Grants for For profit organizations other than small businesses - Science and Technology

The ConTech Call by MEXT is a grant aimed at supporting innovative solutions that improve construction efficiency, productivity, and sustainability, particularly in areas like engineering, energy, and business intelligence, to help shape the future of city design.

This grant provides funding for U.S. researchers and institutions to advance the understanding of the Sun's impact on the solar system, encouraging collaboration with international partners.

Leap Funding, provided by Main Street Ventures, offers equity-free funding ranging from $10,000 to $30,000 to promising, revenue-generating businesses. The primary goal of this program is to help these businesses scale their community impact and enhance their long-term survival prospects. Main Street Ventures' mission, as evidenced by this grant, is to foster economic growth and community development by supporting local enterprises, particularly within the Greater Cincinnati region. This aligns with a strategic priority to strengthen local economies through direct investment in businesses that demonstrate strong potential and customer demand. The target beneficiaries of Leap Funding are established business entities, specifically C-Corps, S-Corps, or LLCs, that possess a Federal Tax ID (EIN). The program focuses on businesses within key industry areas, including retail storefronts (restaurants, coffee shops, retail shops), manufactured goods (consumer packaged goods, clothing, sporting goods), and technology companies (hardware, software). A critical geographical focus is the Greater Cincinnati region, encompassing specific counties in Ohio (Hamilton, Butler, Clermont, Warren), Kentucky (Boone, Campbell), and Indiana (Dearborn). Grant requests from outside this region are explicitly not considered. The program prioritizes funding for specific growth projects rather than general operating expenses. Main Street Ventures defines a growth project as a step that will accelerate business expansion. Suitable direct expenses include key equipment, packaging support, and technology product development. Conversely, general operating expenses such as existing payroll, rent, insurance, marketing, and legal fees are not eligible for grant funds. Businesses are also required to demonstrate customer demand and consistent progression since their founding, ensuring that the funding supports businesses with a proven track record and clear growth trajectory. Expected outcomes include accelerated business growth, increased community impact, and improved long-term survival rates for the funded enterprises. Measurable results would likely include job creation, increased revenue for the businesses, expansion into new markets, or enhanced product development. Special consideration is given to women and minority-owned businesses, as well as those that can secure matching funds from other sources, reflecting a strategic priority to promote diversity and leverage additional investment. The foundation's theory of change appears to be that by providing targeted, equity-free capital for specific growth initiatives, they can empower local businesses to expand, thereby creating a ripple effect of economic benefit and community resilience within the Greater Cincinnati area.

This grant provides funding to higher education institutions and organizations to improve faculty skills in using educational technology and assistive tools in special education programs, enhancing learning for students with disabilities.

The DOD Pancreatic Cancer, Translational Research Partnership Award is a funding opportunity designed to support collaborative research projects between clinicians and scientists, with the aim of accelerating the development and application of innovative ideas in pancreatic cancer treatment, prevention, diagnosis, and survivorship, and encouraging the reciprocal exchange of knowledge between basic and clinical science.

This funding opportunity supports innovative research projects aimed at making significant advancements in breast cancer prevention, diagnosis, and treatment, involving collaboration with breast cancer survivors as advocates.

The Research Infrastructure in the Social and Behavioral Sciences Program (RISBS) supports projects that create computational tools and data to facilitate basic research in the social and behavioral sciences that can lead to improved health, prosperity and security. Projects should be aimed at creating computational tools and data to enable research by social scientists. Examples include, but are not limited to, data collection or assembly efforts that result in new resources for a community of researchers or software platforms that facilitate data collection efforts by others. RISBS does not support research by PIs except in service of creation of the infrastructure. Innovation is especially encouraged. RISBS directly supports three key longitudinal surveys and panel studies that provide researchers with data on how American society functions and changes over time (and in 2010 were recognized as among the 60 most significant "discoveries or advances that... have had a large impact or influence on every Americans life... call[ed] the Sensational 60, in honor of NSFs 60th anniversary): The American National Election Study, which started in 1948 and has been funded by NSF since 1977, provides gold standard data on voting, public opinion, and political participation in U.S. national elections. The General Social Survey, a nationally representative interview survey of the U.S. adult population, collects data on a wide range of topics and has been funded by NSF since its inception in 1972. The Panel Study of Income Dynamics, a longitudinal survey of a nationally representative sample of U.S. families begun in 1968 (with NSF taking over most of its funding in 1980) collects data on a wide array of economic, social and health factors. The RISBS program administers separate solicitations for the American National Election Study (ANES), the General Social Survey (GSS) and the Panel Study of Income Dynamics (PSID). These solicitations have specific requirements and submission deadlines. Other infrastructure proposals may be submitted directly to the RISBS program at any time or transferred from other SBE programs following the respective programs submission guidelines. RISBS also collaborates with other programs in the social and behavioral sciences through a co-funding process to support projects that create especially valuable tools for researchers in those fields or are furthering innovations in research infrastructure. Prospective PIs may also be interested in the Human Networks and Data Science Program Infrastructure(HNDS-I), which supports proposals addressing the development of data resources and relevant analytic techniques that support research in the social, behavioral and economic sciences.Prospective PIs are strongly encouraged to contact the RISBS program officers and/or program officers from other SBE programs that may be applicable to the proposal before submitting to RISBS and to refer to the NSF Proposal Award Policies Procedures Guide (PAPPG) policies on duplicate or substantially similar proposals.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at [email protected], but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The Women’s Business Development Council (WBDC) is offering the Torrington Grant Program, a grant designed to foster the growth of businesses located in Torrington, Connecticut. This initiative aligns with the WBDC's mission to support and empower businesses, particularly by providing crucial financial assistance that can contribute to economic development within the targeted city. The program specifically excludes the use of funds for operating expenses, real estate improvements, reimbursement for past purchases, or debt repayment, emphasizing a focus on growth-oriented investments rather than day-to-day operational costs. The primary beneficiaries of this grant are for-profit businesses situated in Torrington, Connecticut, that meet specific criteria. These businesses must have been in operation for at least two years with a record of sales, demonstrate annual sales/revenue between $25,000 and $2,000,000 in the last twelve months, be registered in Connecticut, and hold a zoning permit from the City of Torrington. Additionally, they must be in good standing with the CT Department of Revenue Services, possess an established business checking account, and utilize a formal digital bookkeeping/financial system. The owner must also be at least 18 years old. The impact goal is to stimulate economic vitality and stability within Torrington by supporting established local businesses. The program prioritizes businesses that are poised for growth and are operating within a structured financial framework. There is a clear focus on financial transparency and stability, as evidenced by the requirement for digital bookkeeping systems and good standing with the Department of Revenue Services. Certain types of businesses are explicitly ineligible, including childcare businesses (though WBDC offers other programs for them), businesses that have previously received a WBDC grant, current WBDC vendors or contractors, and a range of businesses such as medical marijuana, liquor stores, adult businesses, vape/tobacco shops, gambling-related businesses, gun stores, cash advance/pawn shops, and collection agencies. This selectivity ensures that the grants are directed towards businesses that align with the WBDC's strategic vision for community development and ethical business practices. Grants will range from $2,500 to $10,000. The expected outcomes include a measurable increase in the capacity and reach of the recipient businesses, contributing to job creation and sustained economic activity within Torrington. By providing financial resources to qualifying businesses, the WBDC aims to strengthen the local business ecosystem and encourage long-term prosperity. This grant program is a direct manifestation of the WBDC's strategic priority to support local economies through targeted financial aid, operating under the theory of change that direct investment in compliant, established businesses will lead to enhanced economic stability and growth.

This funding opportunity supports educational institutions, nonprofits, and government agencies in Hawaiʻi to develop projects that boost local business growth, job creation, and sustainability on the island.

This funding opportunity provides $5 million to support the deployment and commercialization of innovative technologies in public transportation, aimed at federal, state, local, and tribal governments, as well as public transit providers and educational institutions.

This grant provides matching funds to commercial property owners and businesses in specific zoning districts of Libertyville, Illinois, to improve the appearance and condition of their buildings and sites.

The Visit BG Ohio 2025 Tourism Grant Program offers financial support ranging from $1,000 to $10,000 for projects, events, and activities that promote tourism, increase overnight stays, and provide economic benefits to the City of Bowling Green, with a focus on capital improvement, sports, conferences, festivals, large events, and arts and culture.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports clinical research projects that extend or enhance existing breast cancer studies, requiring collaboration with consumer advocates to improve outcomes for patients and the community.

This grant provides funding to support research and initiatives that promote diversity, equity, inclusion, and accessibility for individuals with disabilities in STEM fields and education.

This funding program provides financial and strategic support to early-stage for-profit start-ups developing innovative solutions to combat climate change, particularly those benefiting underserved communities in select U.S. cities.

This funding opportunity is designed to support organizations in Beltrami County that provide housing solutions, including construction, rehabilitation, and supportive services, to improve the availability and affordability of safe housing for low to moderate-income families and individuals.